Publicaciones en colaboración con investigadores/as de Centro de Investigación Biomédica en Red sobre Enfermedades Hepáticas y Digestivas (30)

2023

  1. Metabolic dysfunction–associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment

    Journal of Physiology and Biochemistry, Vol. 79, Núm. 4, pp. 869-879

2022

  1. Design and validation of a tunable inertial microfluidic system for the efficient enrichment of circulating tumor cells in blood

    Bioengineering and Translational Medicine, Vol. 7, Núm. 3

  2. The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1185-1198

2020

  1. Brain ventricular enlargement in human and murine acute intermittent porphyria

    Human molecular genetics, Vol. 29, Núm. 19, pp. 3211-3223

2019

  1. Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know

    CardioVascular and Interventional Radiology, Vol. 42, Núm. 9, pp. 1262-1270

2017

  1. Conversion from calcineurin Inhibitor-Based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation

    Annals of Transplantation, Vol. 22, pp. 141-147

  2. Immune checkpoint inhibitors for the treatment of hepatocellular carcinoma

    Immunotherapy of Hepatocellular Carcinoma (Springer International Publishing), pp. 51-68

  3. Modulating Immune Responses to Overcome Resistance in Hepatocellular Carcinoma

    RESISTANCE TO MOLECULAR THERAPIES FOR HEPATOCELLULAR CARCINOMA (SPRINGER INTERNATIONAL PUBLISHING AG), pp. 25-43

  4. Phase 1–2 pilot clinical trial in patients with decompensated liver cirrhosis treated with bone marrow–derived endothelial progenitor cells

    Translational Research, Vol. 188, pp. 80-91.e2

2016

  1. Controlling Diabetes after Liver Transplantation: Room for Improvement

    Transplantation, Vol. 100, Núm. 10, pp. e66-e73

  2. Factors related to increased resting energy expenditure in men with liver cirrhosis

    European Journal of Gastroenterology and Hepatology, Vol. 28, Núm. 2, pp. 139-145

2015

  1. Immune monitoring of immunosuppression withdrawal of liver transplant recipients

    Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116

  2. Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation

    Liver International, Vol. 35, Núm. 5, pp. 1590-1596

2014

  1. Comparación de las sondas M y XL para estimar la rigidez hepática por medio de elastografía de transición

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 4, pp. 233-239

  2. Partial liver volume radioembolization induces hypertrophy in the spared hemiliver and no major signs of portal hypertension

    HPB, Vol. 16, Núm. 3, pp. 243-249

2013

  1. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma

    Journal of Hepatology, Vol. 59, Núm. 4, pp. 753-761

  2. Increased liver stiffness values in patients with heart failure

    Acta Gastro-Enterologica Belgica, Vol. 76, Núm. 2, pp. 246-250

  3. Locoregional transarterial therapies for hepatocellular carcinoma: Transarterial chemoembolization and radioembolization

    Viszeralmedizin: Gastrointestinal Medicine and Surgery, Vol. 29, Núm. 2, pp. 92-102

  4. Lung cancer screening with low-radiation dose computed tomography after liver transplantation

    Annals of Transplantation, Vol. 18, Núm. 1, pp. 587-592

  5. Prognostic factors and prevention of radioembolization-induced liver disease

    Hepatology, Vol. 57, Núm. 3, pp. 1078-1087